Drug Utilization Review Board
Meeting Agenda
Thursday, March 13, 2025
7:15 a.m. to 8:30 a.m.
Google Meet joining info
Video call link: meet.google.com/zue-rrqz-rpb
Or dial: (US) +1 904-900-0180 PIN: 172 873 306#
Persons who wish to address the DUR Board may contact Luis Moreno at lmoreno@utah.gov prior to the meeting, or sign up to provide comments at the meeting. Public comments will be limited to 3 minutes per speaker or organization due to time constraints.
1) Call to order - Luis Moreno, PharmD
a) Welcome and Introductions - Luis Moreno, PharmD
Housekeeping
b) Review and Approval of Minutes
2) P&T Update - Ngan Huynh, PharmD
3) Review
a) Aucatzyl (obecabtogene autoleucel) - Luis Moreno, PharmD
i) Public Comment
ii) Committee Discussion/Questions
iii) Committee Action
b) Breyanzi (lisocabtagene maraleucel) - Luis Moreno, PharmD
i) Public Comment
(1) Bristol Myers Squibb - Alexandra Kaiser, PharmD
ii) Committee Discussion/Questions
iii) Committee Action
c) Kymriah (tisagenlecleucel) - Ngan Huynh, PharmD
i) Public Comment
(1) Novartis - Susie Moroney, PharmD
ii) Committee Discussion/Questions
iii) Committee Action
d) Tecartus (brexucabtagene autoleucel) - Ngan Huynh, PharmD
i) Public Comment
ii) Committee Discussion/Questions
iii) Committee Action
4) Next Meeting
a) April 10, 2025 - Alyftrek & Other CFTR Modulators for Cystic Fibrosis Review
5) Adjourned
Notice of Special Accommodations (ADA)
In compliance with the Americans with Disabilities Act, individuals needing special accommodations (including auxiliary communicative aids and services) during this meeting should notify Luis Moreno at lmoreno@utah.gov or (801) 538-6155.
Notice of Electronic or Telephone Participation
Video call link: meet.google.com/zue-rrqz-rpb
Or dial: (US) +1 904-900-0180 PIN: 172 873 306#